Pfizer Inc. (NYSE:PFE) was downgraded by equities researchers at Vetr from a “strong-buy” rating to a “buy” rating in a research note issued on Thursday. They currently have a $36.36 price target on the biopharmaceutical company’s stock. Vetr‘s price objective would indicate a potential upside of 10.99% from the company’s current price.
A number of other brokerages also recently commented on PFE. Deutsche Bank AG reiterated a “buy” rating and set a $44.00 price target on shares of Pfizer in a report on Thursday, August 18th. Credit Suisse Group AG reissued an “outperform” rating and issued a $40.00 target price on shares of Pfizer in a research report on Monday, August 22nd. Piper Jaffray Cos. set a $54.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Tuesday, August 23rd. Jefferies Group set a $41.50 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Thursday, July 14th. Finally, Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, July 20th. Eleven analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $38.59.
Shares of Pfizer (NYSE:PFE) traded down 0.94% during midday trading on Thursday, reaching $32.76. 24,182,290 shares of the company traded hands. The company’s 50 day moving average is $34.08 and its 200-day moving average is $34.25. Pfizer has a 12 month low of $28.25 and a 12 month high of $37.39. The stock has a market capitalization of $198.71 billion, a price-to-earnings ratio of 29.04 and a beta of 0.86.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.02. The business earned $13.10 billion during the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The company’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.56 earnings per share. Equities research analysts forecast that Pfizer will post $2.46 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be issued a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 3.66%. The ex-dividend date is Tuesday, November 8th. Pfizer’s dividend payout ratio (DPR) is 95.24%.
Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in shares of Pfizer by 1.6% in the second quarter. Vanguard Group Inc. now owns 383,339,513 shares of the biopharmaceutical company’s stock valued at $13,497,386,000 after buying an additional 6,193,821 shares during the period. BlackRock Fund Advisors increased its position in shares of Pfizer by 3.2% in the second quarter. BlackRock Fund Advisors now owns 95,416,739 shares of the biopharmaceutical company’s stock valued at $3,359,623,000 after buying an additional 2,927,618 shares during the period. Wellington Management Group LLP increased its position in shares of Pfizer by 5.0% in the first quarter. Wellington Management Group LLP now owns 82,813,816 shares of the biopharmaceutical company’s stock valued at $2,454,601,000 after buying an additional 3,936,078 shares during the period. Franklin Resources Inc. increased its position in shares of Pfizer by 16.7% in the first quarter. Franklin Resources Inc. now owns 62,902,993 shares of the biopharmaceutical company’s stock valued at $1,864,446,000 after buying an additional 9,005,107 shares during the period. Finally, BlackRock Group LTD increased its position in shares of Pfizer by 0.9% in the second quarter. BlackRock Group LTD now owns 60,027,464 shares of the biopharmaceutical company’s stock valued at $2,113,568,000 after buying an additional 552,493 shares during the period. 69.66% of the stock is owned by institutional investors.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.